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The Cre/lox system is a potent technology to control gene expression in mouse tissues. However, 
cardiac-specific Cre recombinase expression alone can lead to cardiac alterations when no loxP sites are 
present, which is not well understood. Many loxP-like sites have been identified in the mouse genome 
that might be Cre sensitive. One of them is located in the Dmd gene encoding dystrophin, a protein 
important for the function and stabilization of voltage-gated calcium (Cav1.2) and sodium (Nav1.5) 
channels, respectively. Here, we investigate whether Cre affects dystrophin expression and function 
in hearts without loxP sites in the genome. In mice expressing Cre under the alpha-myosin heavy 
chain (MHC-Cre) or Troponin T (TNT-Cre) promoter, we investigated dystrophin expression, Nav1.5 
expression, and Cav1.2 function. Compared to age-matched MHC-Cre− mice, dystrophin protein level 
was significantly decreased in hearts from MHC-Cre+ mice of more than 12-weeks-old. Quantitative RT-
PCR revealed decreased mRNA levels of Dmd gene. Unexpectedly, calcium current (IcaL), but not Nav1.5 
protein expression was altered in those mice. Surprisingly, in hearts from 12-week-old and older TNT-
cre+ mice, neither IcaL nor dystrophin and nav1.5 protein content were altered compared to TNT-Cre−. 
Cre recombinase unpredictably affects cardiac phenotype, and Cre-expressing mouse models should be 
carefully investigated before experimental use.
Over the past decades, different genome manipulation technologies have been developed to investigate the 
function of specific genes in vivo. The Cre/loxP system has been of particular interest since it offers the pos-
sibility to generate tissue-specific and time-dependent knock-in (KI) or knock-out (KO) mice1,2. To generate 
cardiomyocyte-specific KO mice, Cre recombinase is often placed under the α-myosin-heavy chain (MHC) and 
the Troponin T (TNT) promoters. To date, many murine MHC- and TNT-Cre strains have been generated on 
different genetic backgrounds. Constitutive Cre expression under the control of MHC promoter can however 
decrease the cardiac ejection fraction in an age-dependent manner3. One potential mechanism to explain the 
side effects of Cre expression is the presence of loxP-like sites in the wild-type genome that are sensitive to Cre 
activity3,4. One of these loxP-like site is localized in the Dmd gene that encodes the structural protein dystrophin3. 
This 427-kilodalton protein is crucial to maintain the integrity of the lateral membrane of cardiac myocytes5. The 
absence of dystrophin in dystrophinopathies such as Duchene muscular dystrophy alters the current mediated 
by the voltage-gated calcium channel Cav1.2 (ICaL) and the whole-cell protein content of voltage-gated sodium 
channel Nav1.56–9. Based on these observations and knowing that Cav1.2 and Nav1.5 are pivotal players in cardiac 
function, we compared dystrophin protein expression, ICaL, and whole-cell Nav1.5 protein expression in hearts 
between MHC-Cre−, MHC-Cre+, TNT-Cre−, and TNT-Cre+ mice.
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Results
Dystrophin expression is reduced in an age-dependent manner in MHC-Cre+ mouse hearts. 
Dmdflox+ mice were generated (Suppl. Fig. 1) and used as a control for the Cre recombinase activity under the 
control of MHC promoter. Western blots were performed using heart lysates from 12-weeks-old wild-type (WT; 
Dmdflox−/MHC-Cre−), MHC-Cre+ (Dmdflox−/MHC-Cre+), and dystrophin KO (Dmdflox+/MHC-Cre+) littermate 
mice. Dystrophin expression was efficiently suppressed in dystrophin KO compared to WT hearts (Fig. 1A). 
Interestingly, dystrophin expression was also greatly reduced in the non-floxed MHC-Cre+ littermates (Fig. 1A, 
compare lane 2 and 6 with lane 3–5). In contrast, the presence of the floxed element did not affect the dys-
trophin expression in heart lysates (Suppl. Fig. 2). To address the time course of dystrophin decrease due to 
the expression of Cre only, western blots were performed on hearts from 8-, 10-, 12-, and 26-week-old mice. 
The reduction in dystrophin expression seemed to be more pronounced with age (Fig. 1B). To statistically con-
firm the age-dependent loss of dystrophin expression, western blots were performed on hearts from 8-, 12-, and 
≥12-week-old MHC-Cre+ mice and control littermates (MHC-Cre−). While dystrophin expression differed only 
slightly between control and MHC-Cre+ hearts at 8 weeks, at ≥12 weeks dystrophin expression was significantly 
decreased by 70 ± 10% in MHC-Cre+ hearts compared to controls (MHC-Cre−) (Fig. 2A,B). Immunostainings 
on cardiac sections from ≥12-week-old MHC-Cre+ mouse hearts showed reduced dystrophin expression at the 
lateral membrane compared to their littermate controls (MHC-Cre−) (Fig. 3A).
Dmd mRNA expression is reduced in MHC-Cre+ hearts. The reduced expression of dystrophin, 
leaded us to perform quantitative RT-PCR on mRNAs extracted from ≥12-week-old mouse hearts. The rela-
tive decrease of 2exp−(ΔCT) measured with MHC-Cre+ hearts corresponded to a ~50% reduction in Dmd mRNA 
level in MHC-Cre+ compared to the control mice (MHC-Cre−) (Fig. 3B). This indicates that the Cre-mediated 
decrease of dystrophin protein correlates with a decrease of Dmd mRNA expression.
calcium current IcaL but not nav1.5 expression is altered in MHC-Cre+ cardiomyocytes. 
Considering the role of dystrophin in the regulation of Cav1.2 currents, we recorded calcium currents in 
MHC-Cre+ isolated cardiomyocytes9. Calcium current densities recorded in isolated cardiomyocytes were 
decreased in cardiomyocytes from ≥12-week-old MHC-Cre+ mice compared to controls (MHC-Cre−) in con-
trary to what it has been previously reported9 or observed in the dystrophin deficient mice used in this study 
(Fig. 4A and Suppl. Fig. 3). Since dystrophin regulates sodium channel stability in cardiac myocytes6,8, we also 
studied Nav1.5 expression in whole-heart lysates from ≥12-week-old mice. Surprisingly, Nav1.5 expression did 
not differ between MHC-Cre+ and MHC-Cre− hearts (Fig. 4B,C).
Figure 1. Dystrophin expression is decreased in adult mouse hearts expressing Cre. (A) Cropped western 
blots showing dystrophin expression in the hearts of WT (Dmdflox−, MHC-Cre−), MHC-Cre+ (Dmdflox−, 
MHC-Cre+), and cardiac-specific dystrophin-KO (Dmdflox+, MHC-Cre+) mice. (B) Cropped western blots 
showing dystrophin expression in mouse hearts at different ages with or without Cre recombinase expression. 
Dystrophin expression is quantified by normalizing band intensity to calnexin band intensity.
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No alterations observed in TNT-Cre+ mouse line. Based on our observations in MHC-Cre+ mouse line, 
we conducted similar experiments on TNT-Cre+ mice, in which Cre recombinase is under the control of the rat 
troponin T2 cardiac promoter10. This strain has been useful for generating early cardiomyocyte-specific mutants 
since Cre is mainly expressed during embryogenesis10. As expected, we observed Cre expression only in new-born 
TNT-Cre+ mouse hearts (Suppl. Fig. 3A,B)10. To validate the recombinase activity of the Cre enzyme under the 
control of the TNT promoter, we crossed TNT-Cre+ mice with mice previously characterized Dlg1flox mice in which 
the SAP97-coding gene Dlg1 was floxed, and compared them to MHC-Cre+ Dlg1flox mice11. SAP97 downregula-
tion was similarly effective in MHC-Cre+ and TNT-Cre+ hearts from ≥12-week-old mice (Fig. 5). No decrease in 
dystrophin protein expression was observed in TNT-Cre+ hearts from ≥12-week-old mice compared to control 
littermates (TNT-Cre−) (Fig. 6A,B). Moreover, neither calcium currents (Fig. 7A) nor Nav1.5 expression (Fig. 7B,C) 
were altered in cardiomyocytes and heart lysates from ≥12-week-old and more TNT-Cre+ mice compared with 
their respective controls.
Discussion
MHC-Cre mice have been extensively used to alter the expression of various cardiac genes12–14. Our present 
work however strongly suggests that the MHC-Cre model should be carefully characterized before using it for 
any experiment, mainly because Cre expression reduces dystrophin protein and mRNA expression. Dystrophin 
is a crucial protein in many cardiac processes, and dystrophin reduction has been observed in human diseased 
cardiomyocytes5. Secondly, the L-type calcium current density is decreased by about 40% in the MHC-Cre model. 
Calcium current is pivotal for cardiac excitation-contraction coupling, among other processes, and calcium cur-
rent dysregulation has been implied in many cardiac arrhythmias15.
The observations that protein expression of the sodium channel Nav1.5 is not affected in MHC-Cre+ mice, 
although dystrophin-deficient mdx5cv mice show an overall reduction of Nav1.5 expression is unexpected6. These 
discrepancies may be explained by the fact that dystrophin expression is only reduced from 12 weeks of age in 
MHC-Cre+ mice whereas dystrophin is constitutively absent in mdx5cv mice.
In contrary to the dystrophin-deficient mdx mice showing an upregulation of the calcium current9, in 
MHC-Cre+ mice, the reduction of dystrophin expression correlates with a decrease of ICaL. In addition calcium 
current recordings using the dystrophin deficient mice presented in this study did not reproduced the aforemen-
tioned observations (upregulation of the calcium current9) (Suppl. Fig. 4). Although, overall all these data are 
puzzling, the consequences of the absence of dystrophin on the calcium current is still under debate. The gender, 
the age and probably the genetic background could explain such observations. For example although Rubi and 
colleagues have shown no alteration of calcium current in male aged dystrophin deficient mice (>25 weeks old)16, 
Li and co-workers reported an increase of this conductance in mixed-sex aged dystrophin deficient mice (>25 
weeks old)17. In addition, the discrepancy of effects on calcium current in dystrophin deficient mice between our 
study and the one from Koenig9, using young adult mice (<25 weeks old), could be due to the genetic background 
Figure 2. Dystrophin expression is decreased in MHC-Cre+ mouse hearts in an age-dependent manner. (A) 
Cropped western blots showing dystrophin expression in MHC-Cre− and MHC-Cre+ mouse hearts from 
8-week-old and more than 12-week-old (≥12 weeks) mice. (B) Quantification of dystrophin expression from 4 
to 8 western blots. *p < 0.05 and ****p < 0.0001.
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of the mice used: C57BL/6J and C57BL/10ScSnJ respectively. Overall these data suggest again the importance of 
proper controls when working with animals.
These results presented in this study suggest also that the expression of other genes is probably altered in the 
MHC-Cre model leading to complex and unpredictable side effects.
Surprisingly, we observed that Cre expression under the rat troponin T2 cardiac promoter affected nei-
ther dystrophin expression nor the calcium current. Those differences of phenotype between MHC-Cre+ and 
TNT-Cre+ mice may be explain by two different hypothesis. The first one could be the difference of genetic 
background. Indeed, mice on mixed backgrounds seem to be more resistant to developing cardiac dysfunction 
in response to Cre expression than mice on a pure background18. The second hypothesis could be the “time win-
dow” of Cre activity. Cre recombinase under the TNT promoter is mainly expressed in new-born mice, whereas 
in MHC-Cre+ mice, Cre is constitutively expressed. It is tempting to hypothesize that the off-target effects of Cre 
mainly occur when Cre recombinase is constitutively expressed after the birth, however further investigations are 
required to challenge these hypotheses.
Interestingly, a recent study reported the presence of more than 600 loxP-like sites in the genome of C57Bl/6 
mice one of which present in the gene coding for the dystrophin3. The decrease of mRNA coding for dystrophin 
observed in MHC-Cre+ mice could be due to the Cre recombinase activity on the dystrophin gene containing 
the loxP-like site. However further experiments should be performed to validate this hypothesis. Based on the 
amount of loxP-like sites, we may therefore speculate that other genes and proteins are dysregulated in MHC- and 
TNT-Cre models, which could have various unexpected effects including those observed in this study. Based on 
these observations, one hypothesis to explain the decrease of calcium current densities in MHC-Cre+ ventricular 
cardiomyocytes compared to the control may be due to an unspecific effect of the cre recombinase either on the 
gene coding for the voltage-gated calcium channel or on other genes coding for proteins involved in the regula-
tion of the calcium current. A comprehensive proteomic analysis on MHC-Cre+ and TNT-Cre+ hearts would be 
required to address the effect of Cre expression on the non-floxed genome.
Figure 3. Dystrophin expression is altered in adult MHC-Cre+ mouse hearts at protein and mRNA level. (A) 
Representative immunostainings of three independent experiments showing decreased dystrophin signal (red) at 
the lateral membrane (white arrows), in cardiomyocytes expressing Cre (green). (B) Decreased mRNA levels for 
dystrophin are also observed in adult MHC-Cre+ mouse hearts compared with control littermates (MHC-Cre−). 
*p < 0.05.
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Cre expression alone likely induces a disease-like phenotype that may confound the effects of any Cre-mediated 
gene deletion. Indeed, Buerger et al. have observed dilated cardiomyopathy in MHC-Cre+ mice, further high-
lighting a potential deleterious effect of the Cre recombinase under the control of the MHC promoter14. 
Pugach et al. also reported that prolonged expression of Cre recombinase decreases cardiac function and leads 
to DNA damage, fibrosis, and cardiac inflammation in MHC-Cre+ mice3. Although the constitutive expression 
of Cre in the MHC-Cre model may underlie the aforementioned problems, alternative models all have sizeable 
shortcomings. Firstly, the MHC-MerCreMer mouse line allows inducible rather than constitutive cardiac-specific 
Figure 4. Decreased ICaL and unaltered Nav1.5 expression in MHC-Cre+ mouse cardiomyocytes and mouse 
hearts respectively. (A) Representative traces of ICaL recorded in isolated cardiomyocytes (left panel) and 
quantification of ICaL (right panel) shown a significant downregulation of the calcium current in MHC-Cre+ 
cardiomyocytes compared to the control (MHC-Cre−) from ≥12-week-old mice. ****p < 0.0001. (B) Cropped 
western blots showing Nav1.5 expression in heart lysates from MHC-Cre+ and MHC-Cre− ≥12-week-old mice. 
The bottom panel shows the quantification of Nav1.5 expression normalized to calnexin expression from 7 to 9 
western blots. n.s. indicates a non-statistically significant difference.
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expression of Cre driven by the MHC promoter19. MerCreMer is a fusion protein containing Cre recombinase 
with two modified estrogen receptor ligand-binding domains at both ends. Treatment with oestrogen recep-
tor modulators such as tamoxifen induce Cre expression. Stec et al. however reported that systolic function is 
impaired in a MHC-MerCreMer mouse strain20. Subsequently, two groups showed that tamoxifen-induced Cre 
expression is linked to cardiac fibrosis and DNA damage, leading to heart failure and death21,22.
Cre recombinase expression can also be regulated by a reverse tetracycline transactivator that is specifically 
expressed in the heart23. Cre is produced once the Cre expression repressor doxycycline is removed from food and 
water23. However, to our knowledge, the effect of this approach on cardiac function has not been investigated yet.
Recently, Werfel and colleagues established a promising approach for cardiac gene inactivation by transfer of 
the Cre recombinase gene using adeno-associated viral vectors serotype 9 (AAV9)24. This technology may induce 
cardiac-specific inactivation of the floxed gene without adverse side effects on cardiac function24. However, more 
research is required.
In view of these problems, Olson and colleagues have generated a cardiac-specific transgenic mouse 
using the Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated (Cas) 9 approach. 
Cardiac-specific overexpressing of Cas 9 did not have side effects25. Then, they delivered a single-guide RNA to 
the heart using AAV9. This elegant method may be a better alternative to the Cre/lox system25.
Figure 5. Characterization of adult TNT-Cre+ mouse hearts. (A) Cropped western blots showing the decrease 
of expression of SAP97 in transgenic mouse hearts in which SAP97 alleles (Dlg1) are floxed (Dlg1flox) and breed 
either with TNT-Cre+ or MHC-Cre+ mice.
Figure 6. Dystrophin protein expression is not altered in TNT-Cre+ mouse hearts. (A) Cropped western blots 
showing dystrophin expression in TNT-Cre− and TNT-Cre+ from 8-week-old and 12 or more-week-old (≥12 
weeks) mouse heart lysates. (B) Quantification of cardiac dystrophin expression from ≥12-week-old mice from 
7 western blots. n.s. indicates a non-statistically significant difference.
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In conclusion, the findings of the present study serve as a warning to researchers who use engineered mouse 
lines. Our results strongly suggest that experimenters should carefully chose the proper controls when using 
Cre-expressing mouse models to avoid any misinterpretation.
Figure 7. ICaL and Nav1.5 expression are unaltered in TNT-Cre+ mouse cardiomyocytes and mouse hearts. (A) 
Representative traces of ICaL recorded in isolated cardiomyocytes (left panel) and quantification of ICaL (right 
panel) show that the calcium current is not changed in TNT-Cre+ cardiomyocytes compared to the control 
(TNT-Cre−) from ≥12-week-old mice. n.s. indicates a non-statistically significant difference. (B) Cropped 
western blots showing Nav1.5 expression in heart lysates from ≥12-week-old MHC-Cre+, MHC-Cre−, TNT-
Cre−, and TNT-Cre+ mice. (C) Nav1.5 expression quantification of 4 western blots normalized to calnexin band 
intensity. n.s. indicates a non-statistically significant difference.
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Methods
Parts of these methods have already been published previously11,26,27.
Animals. All experiments involving animals were performed according to the Swiss Federal Animal 
Protection Law and have been approved by the Cantonal Veterinary Administration, Bern. This investigation 
conforms to the Guide for the Care and Use of Laboratory Animals, published by the US National Institutes of 
Health (NIH publication no. 85-23, revised 1996)11,27. All the experiments have been approved by the veterinary 
office of Bern, Switzerland. (TVB number: BE 28/19). Male mice from four different transgenic mouse lines 
were used in this study. Firstly, the B6.FVB-Tg(Myh6-cre) 2182Mds/J line, also known as MHC-Cre, in which 
the cardiac-specific α-myosin-heavy chain (Myh6) promoter drives expression of Cre, was purchased from the 
Jackson Laboratory (stock no. 011038). Secondly, the STOCK Tg (Tnnt2-cre) 5Blh/JiaoJ line, also called TNT-Cre, 
where Cre recombinase expression is under the control of the rat cardiac troponin T2 promoter, was purchased 
from the Jackson Laboratory (stock no. 024240). These mice were bred from a mixed background to C57BL/6J for 
at least one generation upon arrival at the Jackson Laboratory. Thirdly, the Dmdflox and Dlg1flox mouse strains have 
been generated by by PolyGene AG (Rümlang, Switzerland) (Supplementary Fig. 1)11.
For all experiments, animals were anesthesised by intraperitoneal injection of ketamine/xylazine solution 
(200 mg/kg ketamine and 20 mg/kg xylazine) and killed by cervical dislocation.
Protein extraction and western blot. Whole hearts were extracted from mice, the atria were removed, 
and ventricles were homogenized in 1 mL lysis buffer (50 mM HEPES, 150 mM NaCl, 1 mM EGTA, 10% glycerol, 
1.5 mM MgCl2, and Complete® protease inhibitor cocktail (Roche, Basel, Switzerland)) using a Polytron. Triton 
X-100 in lysis buffer was then added to make a final concentration of 1% (final lysate volume 2 mL). Samples 
were lysed on a rotating wheel for 1 hour at 4 °C. Soluble fractions of the mouse heart lysate were obtained by 
subsequent centrifugation at 13,000 rpm for 15 minutes at 4 °C. To be able to load similar protein amounts from 
each sample on a gel, protein concentrations were measured in triplicate by Bradford assay and extrapolated on a 
bovine serum albumin (BSA) standard curve. Samples were denatured at 95 °C for 5 minutes prior to gel loading. 
To analyse and compare protein expression, 80 μg of each ventricular mouse heart lysate sample was loaded on a 
homemade 1.5 mm-thick 8–15% SDS-PAGE gel for high molecular weight proteins. Gels were run at 150 V for 
1 hour and proteins were subsequently transferred to nitrocellulose membranes using the Biorad Turbo Transfer 
System (Biorad, Hercules, CA, USA). All membranes were stained with Ponceau as a qualitative check for equiva-
lent total protein loading and transfer. Membranes were then rinsed twice with PBS before western blotting using 
the SNAP i.d. system (Millipore, Zug, Switzerland). Membranes were blocked with 1% BSA (Sigma) for 10 min-
utes, followed by incubation with primary antibodies for 10 minutes. Membranes were subsequently washed four 
times in PBS + 0.1% Tween before incubating with secondary fluorescence antibodies for 10 minutes. After four 
more washes with PBS + 0.1% Tween and three washes in PBS, fluorescently labelled proteins were detected on 
a Odyssey® Infrared Imaging System (LI-COR Biosciences, Bad Homberg, Germany). The protein content was 
subsequently quantified by measuring and comparing band densities (equivalent to fluorescence intensities of the 
bands) using the Image Studio software version 5.2.511,26,27.
Immunohistochemistry of mouse ventricular section. Following removal of atria, hearts were cut 
transversally, embedded in Tissue-Tek® O.C.T™ Compound (Sakura Finetek, Zoeterwoude, the Netherlands), 
and cryo-preserved. Frozen 10 μm-thick sections were stored at −80 °C until later use. Sections were then thawed 
to room temperature for 30 minutes and subsequently fixed in ice-cold acetone for 10 minutes. Samples were 
dried at room temperature for 10 minutes. After rinsing in PBS, sections were blocked in PBS with 0.5% Triton 
X-100, 1% BSA, and 10% normal goat serum for 30 minutes. Sections were rinsed again in PBS before addition 
of primary antibodies (in PBS with 0.5% Triton X-100, 1% BSA, and 3% normal goat serum). After 2 hours of 
incubation, sections were rinsed again in PBS and then incubated for 1 hour with secondary antibodies. After a 
final wash with PBS, FluorSave™ Reagent (Calbiochem, La Jolla, CA, USA) was applied to the sections, which 
were then stored at 4 °C and analysed on a confocal microscope (Zeiss Z-710)26.
Antibodies. For western blots, a mouse monoclonal anti-dystrophin antibody (NCL-DYS2, Novocastra, 
Muttenz, Switzerland) was used at a dilution of 1/250. A mouse monoclonal antibody against SAP97 
(VAM-PS005F, Enzo life science, Lausen, Switzerland) was used at a dilution of 1/500. Against Nav1.5, a 
custom-made rabbit polyclonal antibody (Pineda Antibody Service, Berlin) was used at a dilution of 1/200. A 
rabbit polyclonal antibody against Cre (69050; Novagen, EMD Millipore-MERK, Schaffhausen, Switzerland) was 
used at a dilution of 1/500 and a rabbit polyclonal antibody against calnexin (C4731; Sigma-Aldrich, Saint-Louis 
Missouri, USA) was used at 1/100011,26,27.
For immunostainings, rabbit polyclonal antibody against Cre (69050; Novagen, EMD Millipore-MERK, 
Schaffhausen, Switzerland) was used at a dilution of 1/500 and mouse monoclonal anti-dystrophin (Dys 
NCL-DYS2, Novocastra, Muttenz, Switzerland) was used at a dilution of 1/25011,26,27.
RNA extraction and quantitative RT-PCR. Total RNA was isolated from mouse heart pieces with the 
ExpressArt RNAready kit (Amp Tec GmbH, Germany, provided by the lab of professor Jaggi, Bern, Switzerland). 
The High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Life Technologies, Switzerland) 
was used to synthesize cDNA. Subsequently, 25 ng of cDNA was mixed with TaqMan Universal Master Mix 
(Invitrogen) and 1 µL of either dystrophin (Dmd) or glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
probe/primer mix (Applied Biosystems; Mm00464475_m1 and Mm99999915_g1, respectively). GAPDH was 
used as the reference gene to which experimental data was normalized. All samples were loaded in quadru-
plicates. On an ABI 7500 RT-PCR machine, samples were run with the following thermal cycling conditions: 
holding stage at 95 °C for 20 seconds, then 40 cycles of 95 °C for 3 seconds and 60 °C for 30 seconds. Relative Dmd 
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expression (ΔCT) was calculated by subtracting the signal threshold cycle (CT) of the control (GAPDH) from 
the CT value of Dmd. Results were then linearized by calculating 2exp−(ΔCT)11.
Isolation of mouse ventricular myocytes. Single cardiomyocytes were isolated according to a modified 
procedure of established enzymatic methods. Briefly, mice were euthanized by cervical dislocation. Hearts were 
rapidly excised, cannulated and mounted on a Langendorff column for retrograde perfusion at 37 °C. Hearts 
were rinsed free of blood with a nominally Ca2+-free solution containing (in mM): 135 NaCl, 4 KCl, 1.2 MgCl2, 
1.2 NaH2PO4, 10 HEPES, 11 glucose, pH 7.4 (NaOH adjusted), and subsequently digested by a solution supple-
mented with 50 µM Ca2+ and collagenase type II (1 mg/mL, 300 U/mg, Worthington, Allschwil, Switzerland) for 
15 minutes. Following digestion, the atria were removed and the ventricles transferred to nominally Ca2+-free 
solution, where they were minced into small pieces. Single cardiac myocytes were liberated by gentle trituration 
of the digested ventricular tissue and filtered through a 100 µm nylon mesh. Ventricular mouse cardiomyocytes 
were used after an extracellular calcium increase procedure to avoid calcium overload when applying extracellular 
solutions in electrophysiology assays11,26,27.
Electrophysiology. Whole-cell currents were measured at room temperature (22–23 °C) using a VE-2 
amplifier (Alembic Instrument, USA). The internal pipette solution was composed of (in mM) 60 CsCl, 70 
Cs-aspartate, 1 MgCl2, 10 HEPES, 11 EGTA and 5 Mg-ATP, pH 7.2, with CsOH. The external solution contained 
(in mM) 130 NMDG-Cl, 5 CsCl, 2 CaCl2, 1.2 MgCl2, 10 HEPES and 5 D-glucose, pH 7.4, with CsOH. Data were 
analysed using pClamp software, version 10.2 (Axon Instruments, Union City, California, USA). Calcium current 
densities (pA/pF) were calculated dividing the peak current by the cell capacitance11,26,27.
Statistical analyses. Data are represented as means ± S.E.M. Statistical analyses were performed using 
Prism7 GraphPad™ software. Mann-Whitney two-tailed U test was used to compare two groups. One-way 
ANOVA followed by Sidak’s multiple comparisons test was used to compare more than two groups. p < 0.05 was 
considered significant.
Data availability
All data underlying the results are available as part of the article and no additional source data are required.
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